BioSpace News Archive

LifeQ, the company that uses globally-recognized watch brands to gather personalized, clinical-grade data, announced it can detect as many as 40 sleep and cardiovascular disorders with smart watches and other wearable devices, with an anticipated 100 diseases and disorders within the next two years—revolutionizing healthcare and improving consumers’ lives.

Results from the Phase 2b clinical trial of TAK-279 (formerly NDI-034858), a novel allosteric TYK2 inhibitor developed by Nimbus Therapeutics and owned by Takeda (TSE:4502/NYSE:TAK), in patients with moderate-to-severe plaque psoriasis were presented on Saturday, March 18, 2023 at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans.

Cue Health (“Cue”) (Nasdaq: HLTH), a healthcare technology company, today announced it has received Emergency Use Authorization (EUA) from the United States Food and Drug Administration (FDA) for its molecular test to detect the mpox virus (formerly known as monkeypox).

Sirnaomics Ltd. (the “Company”, Stock Code: 2257.HK, and together with its subsidiaries, the “Group” or “Sirnaomics”) announced today that Dr. Patrick Lu, Chairman of the Board, Executive Director, President and Chief Executive Officer and Dr. Richard W. Welch, Vice President of Chemistry, Manufacturing, and Controls processes (CMC), will deliver keynote speeches during the 4th Annual RNAi-Based Therapeutic Summit.

American Aires Inc. (CSE: WIFI) (OTC Pink: AAIRF) (the “Company” or “Aires”), a provider of scientifically-proven EMF modulation technology

Progyny, Inc. (Nasdaq: PGNY) today announced that Pete Anevski, Progyny’s Chief Executive Officer, and Mark Livingston, Chief Financial Officer, will participate in a virtual fireside chat at the KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, at 2:15 P.M. Eastern Time.

Genes long known to control the formation of bones before birth also control bone healing later in life, a new study found.

Axiom Real-Time Metrics (“Axiom”), a premier provider of unified eClinical solutions and services focused on small-to-medium life science organizations is celebrating its 22nd Anniversary this month, helping companies deliver clinical results globally.

Phanes Therapeutics, Inc. (Phanes), an emerging leader in innovative discovery research and clinical development in oncology, announced today that the first patient has been dosed in the phase 1 clinical study (NCT05482893) of PT886, a first-in-class native IgG-like bispecific antibody (bsAb) targeting claudin 18.2 and CD47 for the treatment of gastric, gastroesophageal junction and pancreatic adenocarcinomas.

Exagen Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.